Study Targeting EGFR Resistance Mechanisms in NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Antineoplastic Agents
- Adenocarcinoma
- Bronchial Neoplasms
- Carcinoma
- Neoplasms by Histologic Type
- Carcinoma, Bronchogenic
- Neoplasms by Site
- Protein Kinase Inhibitors
- EGFR L858R
- Respiratory Tract Disease
- Lung Neoplasms
- Carcinoma Non-small-cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- Neoplasms
- Respiratory Tract Neoplasms
- EGFR Activating Mutation
- EGFR T790M
- EGFR C797S
- Neoplasms, Nerve Tissue
- EGFR Exon 19 Deletion
- Thoracic Neoplasms
- EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
- Lung Diseases
- EGFR Gene Mutation
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study will include a dose-escalation portion in patients with EGFR-mutated NSCLC who have previously received at least 1 prior EGFR-targeted TKI, followed by expansion groups consisting of patients with tumors harboring specific mutation profiles: EGFR T790M and C797S mutation (Group 1); EGFR T7...
The study will include a dose-escalation portion in patients with EGFR-mutated NSCLC who have previously received at least 1 prior EGFR-targeted TKI, followed by expansion groups consisting of patients with tumors harboring specific mutation profiles: EGFR T790M and C797S mutation (Group 1); EGFR T790M but not C797S (Group 2); or EGFR C797S but not T790M (Group 3).
Tracking Information
- NCT #
- NCT04862780
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon